Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics.
Jessica Pougoue KetchemenHanan BabekerAnjong Florence TikumAnand Krishnan NambisanFabrice Ngoh NjotuEmmanuel NwangeleHumphrey FongePublished in: British journal of cancer (2023)
Using these biologics simultaneously as biparatopic theranostic agents has additive benefits.